

New IT Coordinator Discusses Challenges Ahead

In March, Dr. David Blumenthal, a Harvard professor and a senior health adviser to President Obama's campaign, was appointed to the position of National Coordinator for Health Information Technology in the Health and Human Services Department.

With Congress setting aside billions of dollars in incentives for physicians and hospitals to adopt health IT as part of the



DAVID
BLUMENTHAL, M.D.

American Recovery and Reinvestment Act, one of Dr. Blumenthal's challenges will be defining the "meaningful use" criteria in the law, a definition that will play a major role in determining who is eligible to receive incentives.

In an interview with INTERNAL MEDICINE NEWS, Dr. Blumenthal talked about some of the challenges ahead.

INTERNAL MEDICINE NEWS: As a primary care physician, what do you see as the biggest challenge for physicians in adopting interoperable electronic health records by 2014? Cost? Misaligned incentives? Products that don't meet their needs? Security?

Dr. Blumenthal: Surveys have shown all of those to be issues. I think security is a lesser issue, according to the surveys that my group did at Harvard when I was there. But the cost of acquisition, the lack of return on investment, [and] concern about the usefulness of products all ranked high in our survey results.

IMN: The Recovery Act includes about \$17 billion in incentives for physicians and hospitals to adopt health IT. What impact do you expect this to have?

Dr. Blumenthal: Let me first make a minor correction in the number: \$17 billion is a Congressional Budget Office number and it is actually a combination of two numbers: a spending number and a cost savings number. Both are estimates. The actual CBO projections of spending are about \$29 billion, and they project a \$12 billion savings, which gets you to \$17 billion. So if we think more on the order of \$30 billion or even more than that, I do think that's enough to change the dynamic in the marketplace.

We are also counting to some degree on professionalism to complement the incentives. If physicians were only about money, it would be a much less happy world and the quality of care would be much lower than it is. Physicians don't expect the government to help them buy stethoscopes, examining tables, treadmills for stress tests. They know these are essential to their work as professionals, and I think that is where we are heading with electronic health records as well.

IMN: Everyone is curious to see how the HHS defines the "meaningful use" criteria outlined in the Recovery Act. Is there a consensus building around this term?

Dr. Blumenthal: I think there is a con-

sensus building. We haven't pinned it down finally. We [are] discussing this issue before our Health Information Technology Policy Committee. I think at that point some of the major options will be on the table for review and for public comment. We will ultimately have to go through a regulatory process to finally determine the effective definition, but I'm hoping that over the summer the HHS view of the definition will become clear.

IMN: Can you say where there is consensus so far?

Dr. Blumenthal: I don't want to get into specifics, but I will tell you that I think the consensus is clear around one thing, and that is that we should concentrate on performance and usability rather than on technical specifications. We should be constantly linking our definition of meaningful use to clinically meaningful capabilities and performance attributes.

IMN: You and the president frequently have said that health IT is a tool, not a fix for our health care system. What can we reasonably expect to achieve through the widespread adoption of health IT?

Dr. Blumenthal: There are three essential components for achieving the president's goal and the administration's goal and, I think, the public's goal for a higher-performing health system. The first is better information on what works and what



Mealtime therapy matters inside the body. But it first needs to fit your patient's life.



Achieving mealtime control takes more than insulin alone. That's why the Humalog® 3-Part Approach provides a combination of products, pens, and tools designed to help fit mealtime insulin into your patient's life. To find out more, visit www.humalog.com.

Humanly possible.

Humalog

insulin lispro injection (rDNA origin)

For additional safety profile and other important prescribing considerations, see the accompanying Brief Summary of full Prescribing Information.

doesn't in the daily practice of medicine.

The second is the ability to apply that knowledge rapidly to practice. And it's in that setting that I think health care information technology becomes a vital tool. It enables practitioners to access in real-time and have the benefit of ... the latest information that is approved by their peers and recognized by their peers as valid and useful for patient care.

The third element is changes in the financing and organization of care that make it more valuable and more rewarding for physicians and easier for physicians to take cost and quality into

account when they make their decisions.

Health information technology is the major part of the second [component], but can't function optimally unless all three are in place. So we are vitally dependent for the savings and the quality improvement that could come out of HIT; we are vitally dependent on health care reform more generally.

If physicians are going to realize savings in their practice and gain the benefit of those savings, there will have to be some change in the way that we pay for care and some change in the way that we recognize excellence in medicine so that

physicians, as well as their patients, feel very directly and personally the benefits of making the health care system a better health care system.

IMN: The Recovery Act provides for incentives for HIT adoption starting in 2011, but there are many areas where there are still not uniform standards. Can the industry keep up with this aggressive timetable?

Dr. Blumenthal: Frankly, I think we have most of what we need in the way of standards to permit the physicians to get to meaningful use as it is likely to be defined by 2011. I also think that the in-

dustry can reconfigure their software in time to make it possible for physicians to meet those standards. What I'm mostly concerned about is that—in recognizing those standards and in certifying the software and hardware that we need to certify—we also make certain that we are laying the groundwork for a dramatically improved set of technologies as we go forward. We are looking very hard at how we [can ensure] that when we certify a system and we set a set of standards, we are leaving room for innovation and improvement.

—Interview by Mary Ellen Schneider

Humalog (insulin lispro injection [rDNA origin]) is for use in patients with diabetes mellitus for the control of hyperglycemia. Humalog should be used with longer-acting insulin, except when used in combination with sulfonyleureas in patients with type 2 diabetes.

Humalog is contraindicated during episodes of hypoglycemia and in patients sensitive to Humalog or one of its excipients.

Important Safety Information

Humalog differs from regular human insulin by its rapid onset of action as well as a shorter duration of action. Therefore, when used as a mealtime insulin, Humalog should be given within 15 minutes before or immediately after a meal.

Due to the short duration of action of Humalog, patients with type 1 diabetes also require a longer-acting insulin to maintain glucose control (except when using an insulin pump). Glucose monitoring is recommended for all patients with diabetes.

The safety and effectiveness of Humalog in patients less than 3 years of age have not been established. There are no adequate and well-controlled clinical studies of the use of Humalog in pregnant or nursing women.

Starting or changing insulin therapy should be done cautiously and only under medical supervision.

Hypoglycemia

Hypoglycemia is the most common adverse effect associated with insulins, including Humalog. Hypoglycemia can happen suddenly, and symptoms may be different for each person and may change from time to time. Severe hypoglycemia can cause seizures and may be life-threatening.

Other Side Effects

Other potential side effects associated with the use of insulins include: hypokalemia, weight gain, lipodystrophy, and hypersensitivity. Systemic allergy is less common, but may be life-threatening. Because of the difference in action of Humalog, care should be taken in patients in whom hypoglycemia or hypokalemia may be clinically relevant (eg, those who are fasting, have autonomic neuropathy or renal impairment, are using potassium-lowering drugs, or taking drugs sensitive to serum potassium level).

Humalog® is a registered trademark of Eli Lilly and Company and is available by prescription only.